A Phase 2 interventional study of AndroGel 16.2 mg/L in Hypermetabolism in ICU, Loss of Muscle Mass and Functional Disability After ICU, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by University Hospital, Clermont-Ferrand · Phase 2, Interventional, and Treatment
Dupuis C, Bachoumas K, Oris C, Eisenberg S, Pereira B, Boirie Y, Farigon N, Sapin V, Bernard L, Richard R, Costes F, Adda M, Souweine B. Properties of testoste…PubMed 41242020 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies testing testosterone in Hypogonadism — 9 open to participants now, 11 under way, 3 of them phase 3. Testosterone · Hypogonadism.
Among the 119 studies testing testosterone in Hypogonadism, this one is the 77th largest by enrollment of the 116 interventional ones that give a count, is one of 2 that started in 2019, is one of 33 in phase 2, and was the 101st registered.
320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.
Browse Hypogonadism studies →9 of the 119 studies testing testosterone in Hypogonadism are open now, in 4 countries. Recruiting first, the newest first:
Halozyme Therapeutics · Sites in United States
Ages 12–17 · Men only
Bradley Nindl · Sites in United States
Ages 18–40 · Healthy volunteers
Canisius-Wilhelmina Hospital · Sites in Netherlands
Ages 18+ · Men only
Seattle Institute for Biomedical and Clinical Research · Sites in United States
Ages 18–54 · Men only
North Florida Foundation for Research and Education · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Testosterone: first FDA approval 1953 (DELATESTRYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 24 Hypogonadism studies recruiting now, 9 (38%) set no upper age limit and 12 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 41 · Phase 3 24 · Phase 4 37
First in 2001; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 50 across 243 interventional studies indexed under Hypogonadism.
Median enrollment 49 across the 116 interventional studies. Of the 99 that completed or were terminated, 53 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 119 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 1 study filed under Hypogonadism — fewer than ten, so there is no comparison to draw.
4 of the studies testing testosterone in Hypogonadism that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04301765Seattle Institute for Biomedical and Clinical ResearchImproving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency | 2026-11 |
| NCT04049331Seattle Institute for Biomedical and Clinical ResearchTestosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone | 2027-01-30 |
| NCT06455969Bradley NindlAdaptions and Resiliency to Multi-Stressor OpeRations | 2027-08 |
| NCT01894308Transdermal Delivery Solutions CorpA Dose Ranging Study to Examine TDS-Testosterone 5% | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 119 studies testing testosterone in Hypogonadism, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Critically ill patients experience major insults that lead to increased protein catabolism. Hypermetabolism occurs early and rapidly during the first week of critical illness to provide amino acids for the production of energy via gluconeogenesis, and also for the synthesis of acute phase proteins and repair of tissue damage. During acute phase, neuroendocrine and inflammatory responses promote protein breakdown and amino acid release. Under stress conditions, protein synthesis cannot match the increased rate of muscle proteolysis because of a state of anabolism resistance, which limits uptake of amino acids into muscles. Hypermetabolism results in a significant loss of lean body mass with an impact on weaning from the ventilator and muscle recovery. Functional disability may be long term sometimes with no full return to normal.
In critically ill patients, severe and persistent testosterone deficiency is very common and is observed early after ICU admission. This acquired hypogonadism promotes the persistent loss of skeletal muscle protein and is related to poor outcome.
Administration of testosterone induces skeletal muscle fiber hypertrophy, decreases protein breakdown in healthy young men and burned patients. It has been repeatedly shown that testosterone treatment enhances muscle mass and strength in young and older hypogonadal men and women and can improve physical performance.
Type of trial
TestICUs-1 is a single center open-label parallel randomized controlled study phase II assessing the efficacy of testosterone gel to correct low testosterone serum levels associated with ICU acquired hypogonadism in mechanically ventilated patients with shock. TestICUs-1 will be conducted in the 10-bed medical ICU of the university hospital of Clermont-Ferrand. Study drug is Androgel® 1.62 mg/L approved by the ANSM for the treatment of hypogonadism in men containing 1.62% of testosterone.
Category of research Research involving human subjects aimed at assessing the efficacy of and safety to drug.
Study phase
A study assessing the efficacy of a multimodal strategy including treatment with testosterone gel, (75 mg/day in men and 25 mg/day in women) in improving physical activity in hemodialysis patients is in progress (Americano PHRC N 2012, AE Heng).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AndroGel® AndroGel 16.2 mg/L will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women
Drug: AndroGel 16.2 mg/L
In the control group, AndroGel will not be administered.
Drug page: TestosteroneStudies of TestosteroneTestosterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
Pourcentage of patients with normal median value of serum total testosterone
Pourcentage of patients with median value of serum total testosterone collected from blood samples at day 4, 7, 10, 14 higher than 280 ng/dl in men and 12 ng/dl in women.
Time frame: day 4 to day 14
Proportion of patients with normal median free testosterone serum values
Proportion of patients with median free testosterone serum values at day 4, 7, 10, 14 higher than 58 pg/ml in men and 0,9 ng/ml in women
Time frame: day 4 to day 14
Proportion of patients with normal median serum values of bioavailable testosterone
Proportion of patients with median serum values of bioavailable testosterone at day 4, 7, 10, 14 higher than 75 ng/dl in men 0.8 ng/dl in women
Time frame: day 4 to day 14
Nitrogen balance
Daily and cumulative nitrogen balance from day 1 to extubation
Time frame: daily from day 1 to day 14
Physical performance
Physical performance by Six-minute walk test (6MWT)
Time frame: day 14, 1month and 3 months after ICU discharge
Muscle strength
Muscle strength by MRC (Medical Research Scale)
Time frame: at ICU discharge, 1month and 3 months after ICU discharge
Near Infrared Spectroscopy
Near Infrared Spectroscopy by NIRS test
Time frame: at 14 days
Muscular mass
Muscular mass by L3 computed tomography
Time frame: at ICU discharge and 1month after ICU discharge
Lung function
Lung function by spirometry
Time frame: at 1 and 3 months after ICU discharge
Ran from Jun 2019 to primary completion in Nov 2023, 52 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jun 2025 → Nov 2023 and completion Jun 2025 → Nov 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Dupuis C, Bachoumas K, Oris C, Eisenberg S, Pereira B, Boirie Y, Farigon N, Sapin V, Bernard L, Richard R, Costes F, Adda M, Souweine B. Properties of testoste…PubMed 41242020 ↗
Dupuis C, Bachoumas K, Oris C, Eisenberg S, Pereira B, Boirie Y, Farigon N, Sapin V, Bernard L, Richard R, Costes F, Adda M, Souweine B. Properties of testoste…PubMed 41242020 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Testosterone
University Hospital, Clermont-Ferrand →